"Inosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
| Descriptor ID |
D007288
|
| MeSH Number(s) |
D03.633.100.759.590.616 D13.570.583.616 D13.570.800.573
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Inosine".
Below are MeSH descriptors whose meaning is more specific than "Inosine".
This graph shows the total number of publications written about "Inosine" by people in this website by year, and whether "Inosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Inosine" by people in Profiles.
-
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
-
Intraocular adenosine levels in normal and ocular-hypertensive patients. J Ocul Pharmacol Ther. 2003 Apr; 19(2):113-9.
-
Contributions of adenosine receptor activation to the ocular actions of epinephrine. Invest Ophthalmol Vis Sci. 1999 Aug; 40(9):2054-61.
-
A randomized double-blind study of inosiplex (isoprinosine) therapy in patients with alopecia totalis. J Am Acad Dermatol. 1987 May; 16(5 Pt 1):977-83.
-
An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984 Aug; 11(2 Pt 1):224-30.